Company Overview of Xeris Pharmaceuticals, Inc.
Xeris Pharmaceuticals, Inc., a clinical stage specialty biopharmaceutical company, is engaged in developing non-aqueous formulations of injectable drugs for multiple indications. The company focuses on the development of the soluble and stable glucagon for use in the treatment of diabetes-related and non-diabetic hypoglycemia. It offers G-Pen (glucagon injection), an auto-injectable glucagon pen in Phase 2 clinical development as an alternative to the glucagon emergency kits and used in the emergency treatment of severe hypoglycemia; G-Pen Mini (glucagon injection), a multi-dose and variable-dose glucagon pen in Phase 2 clinical development for the treatment of mild to moderate hypoglycemia ...
3208 Red River Street
Austin, TX 78705
Founded in 2005
Key Executives for Xeris Pharmaceuticals, Inc.
Chief Executive Officer, President and Director
Co-Founder, Executive Vice-President of Corporate Development and Director
Co-Founder, Chief Scientific Officer and Director
Chief Operating Officer and Chief Financial Officer
Compensation as of Fiscal Year 2017.
Xeris Pharmaceuticals, Inc. Key Developments
Xeris Pharmaceuticals, Inc. Appoints John P. Schmid as Board of Directors
Sep 7 17
Xeris Pharmaceuticals, Inc. appointed John P. Schmid as a Board of Directors. John is an accomplished executive with an impressive track record in the healthcare and biotech industry. He brings a wealth of experience and knowledge that comes from building successful life science businesses including taking two companies public and generating significant shareholder value. John will play a key role as Xeris continues executing vision to develop and commercialize novel XeriSol™ and XeriJect™ formulation technologies.
Xeris Pharmaceuticals, Inc. Announces New Results From Ready-To-Use Liquid Glucagon Clinical Development Program
Jun 16 17
Xeris Pharmaceuticals, Inc. announced that results from three clinical studies of the company’s investigational ready-to-use liquid glucagon formulation were presented at the 77th Scientific Session of the American Diabetes Association (ADA) in San Diego from June 9-13, 2017. In a pilot study, patients with Type 1 diabetes (T1D) experienced normalization of plasma glucose levels and demonstrated complete resolution of symptoms of severe, experimentally induced hypoglycemia following a rescue dose of the company’s glucagon formulation. In two proof-of-concept studies, mini-doses of the same glucagon formulation were found to be as effective as carbohydrates at treating or preventing mild-moderate and exercise-induced hypoglycemia. A Pilot Study in Adults with T1DM to Examine the Efficacy of Stable Non-Aqueous Glucagon for Treatment of Severe Hypoglycemia (Abstract 140-LB). This study was conducted in adults with type 1 diabetes to explore whether a subcutaneous injection of liquid-stable glucagon (0.5 or 1 mg) could rescue subjects from insulin-induced severe hypoglycemia. After an overnight fast, subjects were administered intravenous (IV) insulin under controlled conditions to induce plasma glucose < 50 mg/dL for 5 minutes. This procedure resulted in symptoms typical of hypoglycemia in most subjects. Following the 1 mg glucagon dose, 7/7 subjects achieved primary response with plasma glucose > 70 mg/dL in an average time of 11.9 minutes (range: 8.1-15.9 minutes). Following the 0.5 mg dose, 6/6 subjects achieved plasma glucose > 70 mg/dL in an average time of 14.4 minutes (range: 9.5-19.7 minutes). Symptomatic relief began within 5 minutes of dosing with glucagon, and all subjects experienced complete resolution of hypoglycemia symptoms in a median time of 20 minutes (range 10-30). No significant safety concerns were noted. Efficacy and Safety of Mini-dose Glucagon for Treatment of Non-Severe Hypoglycemia in Adults with Type 1 Diabetes (Abstract 1068-P). Twenty adults with type 1 diabetes using an insulin pump and continuous glucose monitor (CGM) and experiencing frequent mild hypoglycemia participated in a crossover trial (two 3-week periods) comparing non-aqueous mini-dose glucagon (MDG) (150 µg) versus oral glucose tablets (TABS) (16 g) to treat hypoglycemia (blood glucose [BG] 40-69 mg/dL). Successful treatment was defined as BG =50 mg/dL at 15 minutes and =70 mg/dL at 30 minutes after intervention. Sixteen participants (mean age 39 years, 75% female, mean diabetes duration 23 years, mean HbA1c 7.2%) had 118 analyzable events with initial BG 50-69 mg/dL. Successful treatment criteria were met for 58 (94%) of 62 events during the MDG period and 53 (95%) of 56 events during the TABS period (adjusted p=0.99). CGM-measured time with blood glucose in the range of 70-180 mg/dL data did not differ between treatment groups during the 2 hours post-events, but TABS resulted in higher maximum glucose (116 vs 102 mg/dL; p=0.01) over the first hour. Some participants reported injection site discomfort (MDG) as well as nausea (MDG and TABS). Patients with type 1 diabetes (T1D) who perform aerobic exercise often experience a decrease in blood glucose concentration that can result in hypoglycemia. Current approaches to prevent exercise-induced hypoglycemia include reduction in insulin delivery or ingestion of carbohydrates, but either strategy can result in hypo- or hyperglycemia. This study sought to determine whether mini-dose glucagon (MDG) given subcutaneously before exercise could prevent subsequent glucose lowering, and to compare the glycemic response to current approaches. The study was a randomized, 4-period crossover trial involving 15 adults with T1D who exercised at 55% VO2max for 45 min with either (1) no intervention (control), (2) 50% basal insulin reduction, (3) 40 g oral glucose tabs, or (4) 150 µg glucagon, administered 5 min. before exercise. During exercise, mean plasma glucose increased slightly with MDG compared to a decrease with control and insulin reduction, and with a greater increase with glucose tabs. Insulin levels were not different, while glucagon increased with MDG. Six subjects experienced hypoglycemia (< 70 mg/dl) during control, 5 during insulin reduction and none with glucose tabs or MDG; 5 subjects experienced hyperglycemia (=250 mg/dl) with glucose tabs and 1 with MDG. No significant safety concerns were noted.
Xeris Pharmaceuticals, Inc. Presents at Pre-Filled Syringes San Diego Summit, Jun-05-2017 04:15 PM
Jun 3 17
Xeris Pharmaceuticals, Inc. Presents at Pre-Filled Syringes San Diego Summit, Jun-05-2017 04:15 PM. Venue: HYATT REGENCY MISSION BAY, 1441 Quivira Road, San Diego, California, United States. Speakers: Benir Ruano, Vice President, Global Manufacturing & Technical Operations.
Similar Private Companies By Industry
Recent Private Companies Transactions
May 17, 2017